Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.81 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | HTR2B | P41595 | 1/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153318 | 1.00 | ADRB2 (0.81) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL29798912 | 1.00 | ADRB2 (0.81) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL4932017 | 0.99 | ADRB2 (0.79) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL3958316 | 0.98 | ADRB2 (0.85) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Succinic Acid SCHEMBL561453 | 0.93 | ADRB2 (0.91) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL10083964 | 0.91 | ADRB2 (0.84) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561592 | 0.91 | ADRB2 (0.90) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL565114 | 0.90 | ADRB1 (0.66) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL153077 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| SCHEMBL560927 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786111-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | claimed |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | claimed |
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-07-10 | — | — | US | claimed |
| US-20070155741-A1 | Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ADRB2 28/4885ADRB1 42/4885CHRM2 5/4885 |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | CHRM1, CHRM2, ADRA2C | ADRB2 6/4885ADRB1 8/4885CHRM2 2/4885 |
| US-20070155741-A1 | Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ADRB2 27/4885ADRB1 38/4885CHRM2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.